| scholarly article | Q13442814 |
| P356 | DOI | 10.1196/ANNALS.1281.025 |
| P698 | PubMed publication ID | 14751837 |
| P50 | author | Ruiwen Zhang | Q29887890 |
| Hui Wang | Q86913613 | ||
| P2093 | author name string | Zhuo Zhang | |
| Sudhir Agrawal | |||
| Patsy Oliver | |||
| P2860 | cites work | The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes | Q24608783 |
| Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. | Q36080896 | ||
| mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line | Q36138865 | ||
| Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents | Q36761728 | ||
| Pharmacology of Therapeutic Oligonucleotides | Q38345416 | ||
| mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein | Q40018842 | ||
| Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation | Q40836669 | ||
| Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. | Q55024311 | ||
| In VivoPharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous Guanosines | Q73488159 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 217-235 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms | |
| P478 | volume | 1002 |
| Q57115778 | Advanced Glycation End Products Increase MDM2 Expression via Transcription Factor KLF5 |
| Q37189998 | Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? |
| Q37389892 | Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo |
| Q36458427 | Antisense-based cancer therapeutics: are we there yet? |
| Q24299167 | Daxx is reciprocally regulated by Mdm2 and Hausp |
| Q39875059 | FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. |
| Q33880170 | Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs |
| Q35925611 | Gene therapy strategies to improve the effectiveness of cancer radiotherapy |
| Q92030437 | Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer |
| Q33480331 | Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? |
| Q36689088 | Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner |
| Q37524156 | Recent advances in validating MDM2 as a cancer target. |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q40392451 | Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics |
| Q38320884 | Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway |
| Q35030217 | Targeting MDM2-p53 interaction for cancer therapy: are we there yet? |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q33927539 | Uric acid protects against secondary damage after spinal cord injury |
Search more.